Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

NVAXNVAX
Showing 8 of 28 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in NOVAVAX INC

Yes. Citadel Advisors holds 1,695,313 shares of NVAX (Novavax), worth $16M, as of its Q2 2026 13F filing. It increased the position by 571,567 shares (+50.9%) from Q1 2026. Citadel Advisors has held NVAX since Q1 2024, across 10 quarterly 13F filings.

Current Value

$16M

Current Shares

1.7M

Total Value Change

+$8.8M

Total Shares Change

+1.1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.7M
+50.9%
$16M0.0%$9.42
39
2026-Q1
Increased
1.1M
+4.7%
$9.1M0.0%$8.14
29
2025-Q4
Decreased
1.1M
-16.5%
$7.2M0.0%$6.72
0
2025-Q3
Increased
1.3M
+55.1%
$11.1M0.0%$8.67
39
2025-Q2
Decreased
829,244
-50.3%
$5.2M0.0%$6.30
0
2025-Q1
Increased
1.7M
+95.4%
$10.7M0.0%$6.41
44
2024-Q4
Increased
853,491
+51.3%
$6.9M0.0%$8.04
38
2024-Q3
Decreased
564,045
-9.5%
$7.1M0.0%$12.63
0

Other major holders of NVAX: FMR LLC, RA CAPITAL MANAGEMENT, L.P., FRANKLIN TEMPLETON INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used